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Abstract
Background: Urinary bladder and renal dysfunction are secondary events associated with spinal cord injury (SCI) in 
humans. These secondary events not only compromise quality of life but also delay overall recovery from SCI 
pathophysiology. Furthermore, in experimental models the effects of SCI therapy on bladder and renal functions are 
generally not evaluated. In this study, we tested whether simvastatin improves bladder and renal functions in a rat 
model of experimental SCI.
Methods: SCI was induced by controlled contusion of T9-T10 in adult female rats. Simvastatin (5 mg/Kg body weight) 
was administered at two hours after SCI and repeated every 24 hours until the end point. Simvastatin-treated SCI 
animals (simvastatin group) were compared with vehicle-treated SCI animals (vehicle group) in terms of the Basso 
Beattie Bresnahan score, tissue morphology, cell death, and bladder/renal functions.
Results: The urinary bladder of vehicle animals showed a 4.3-fold increase in size and a 9-fold increase in wet weight 
compared to sham animals. Following SCI, the urine to plasma osmolality ratio increased initially but decreased 1 week 
after SCI. Hematoxylin and eosin staining of bladder tissue showed transitional epithelial hyperplasia, degeneration of 
lamina propria, and enlargement of tunica adventia in addition to detrusor muscle hypertrophy. Rats treated with 
simvastatin for 14 days displayed remarkable recovery by showing decreased bladder size and maintenance of a 
normal urine/plasma osmolality ratio, in addition to improved locomotion. The muscularis layer of the bladder also 
regained its compact nature in simvastatin animals. Moreover, SCI-induced renal caspase-3 activity was significantly 
decreased in the simvastatin group indicating the ability of simvastatin to reduce the renal tubular apoptosis.
Conclusion: Post-injury administration of simvastatin ameliorates bladder and renal dysfunction associated with SCI in 
rats.
Introduction
Spinal cord injury (SCI) results primarily in the loss of 
motor and sensory functions. Severe SCI often results 
not only in paralysis but also in the loss of sensation and 
reflexes below the point of injury, such as bowel and blad-
der control. Dysfunction of the urinary system is one of 
the most important consequences of SCI. Bladder dys-
function causes hyperarousal, sleep disturbances, and 
disruption of sensorimotor integration. Spinal and 
supraspinal circuitry controls urine storage and release 
[1,2]. Other brainstem nuclei like the raphe magnus, 
raphe pallidus, parapyramidal medullary reticular forma-
tion, subcoeruleus pars alpha, locus coeruleus and A5 
and A7 nuclei are also involved in the bladder external 
urethral sphincter (EUS) pathway [3]. Signals from the 
pons project directly to the S2-S4 sacral segments of the 
spinal cord and control the detrusor and urethral sphinc-
ter activity parasympathetically, resulting in normal stor-
age and voiding [4]. Detrusor-sphincter dyssynergia has 
been reported in SCI patients [5].
Understanding of bladder dysfunction comes from blad-
der outlet obstruction (BOO) [6-8] and experimental 
autoimmune encephalomyelitis (EAE) animal models [2]. 
Although bladder hypertrophy following SCI was 
reported previously [9], the bladder pathophysiology 
associated with SCI has not been thoroughly investigated. 
Since tissue hypertrophy depends on hypertrophying sig-
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nals [10], investigating the pathophysiology of bladder 
dysfunction in SCI patients is significant. We investigated 
the pathophysiology of spinal bladder dysfunction in a rat 
contusion model of SCI. Contusion injuries are created 
by hitting the exposed spinal cord with a mechanical 
device that displaces the spinal cord by a preselected 
amount. The contusion injury model seems to be the 
most relevant to human spinal cord traumatic injury [11].
Current therapeutics for neurogenic bladder include 
functional electrical stimulation (FES) [12]; however, 
exposure to uncontrolled shock has been reported with 
delayed recovery to normal bladder function [13]. Other 
available treatment options include anticholinergics, self 
catheterization, and use of desmopressin, cannabinoids, 
vanilloids, and botulinum neurotoxin [14]. A bladder 
acellular matrix graft (BAMG) has also been shown to 
improve voiding function of SCI-induced hypertrophic 
bladder [15]. Despite the availability of various treatment 
options, catheterization is the most widely used tech-
nique in managing bladder problems with SCI patients. 
However, indwelling urethral catheterization is associ-
ated with complications like bladder stone formation or 
infection and causes significant morbidity [16]. Hence, 
catheter-free bladder maintenance is the ultimate aim of 
studies involving urogenital problems associated with 
SCI [17]. Furthermore, the direct effect of SCI therapies, 
including statins, on bladder and renal functions is not 
known. Therefore, this study investigates the therapeutic 
efficacy of simvastatin for restoring bladder and renal 
functions following SCI.
Statins are FDA-approved cholesterol lowering drugs 
widely used in clinical practice. Studies from our labora-
tory described anti-inflammatory properties of statins in 
a cell culture model [18]. Subsequently, studies from our 
laboratory and others have reported the immunomodula-
tory [19,20] and neuroprotective activities of statins in 
animal models of EAE [21,22]. These pleiotropic effects 
of statins were reported to function independently of 
their cholesterol lowering effects. Statins have also been 
reported to ameliorate the risk associated with metabolic 
syndrome in vascular and chronic kidney disease [23] as 
well as renal inflammatory diseases [24-27]. We observed 
neuroprotective and anti-inflammatory activities of ator-
vastatin in a post-injury treatment rat model of experi-
mental SCI [28]. Since neurogenic bladder and renal 
dysfunction are associated with SCI and statin treatment 
has been reported to protect against SCI, we investigated 
the efficacy of simvastatin for bladder hypertrophy and 
renal dysfunction in a rat model of SCI.
Methods
Materials
Unless otherwise stated, all compounds were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Caspase 3 
antibody (rabbit polyclonal) was from Santa Cruz, CA, 
USA. Simvastatin was purchased from Calbiochem, CA, 
USA.
Animal
The animals used in the present study were female 
Sprague-Dawley rats (225-250 g) purchased from Harlan 
laboratories (Durham, NC). The animal procedures for 
the study were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the Medical University 
of South Carolina.
Experimental design and administration of simvastatin
The experiment consisted of three groups of animals: 
sham operated (sham), vehicle-treated (vehicle), and sim-
vastatin-treated (simvastatin). Simvastatin (5 mg/kg in 
1% methyl cellulose solution) was gavage fed to the ani-
mals at 2 hours after SCI and every 24 hours thereafter 
until the animals were sacrificed. Vehicle and sham ani-
mals were fed with carrier solution alone. Selection of 5 
mg/kg dose of simvastatin is based on our earlier study on 
atorvastatin-mediated neurovascular protection follow-
ing SCI in rats [28].
Controlled contusion spinal cord injury
Animals were anesthetized with ketamine-xylazine cock-
tail (80 mg/kg-10 mg/kg body weight respectively). After 
confirming the validity of anesthesia by toe pinching, the 
animals were depilated on dorsal spine line, and a hemi-
laminectomy was done at the T9-T10 level to expose the 
dura overlying the spinal cord [29]. Spinal cord contusion 
injury was induced by a controlled contusion injury (CCI) 
device described by Bilgen [30]. Injury was made with 2 
mm diameter impactor at 1.5 m/s velocity to a depth of 1 
mm for 85 msec. Following SCI, the wound was irrigated 
with phosphate buffered saline (PBS) solution, and the 
incision was closed in layers, with the skin closed using 
polysorb 4. Sham-operated animals underwent laminec-
tomy only. Animals were returned to their cages and kept 
on a 37°C heating blanket overnight.
Evaluation of locomotor function
The locomotor activities of rats were recorded for 28 days 
according to the Basso Beattie Bresnahan (BBB) open 
field expanded locomotor rating scale [31]. The BBB rat-
ing was described with a 21-point scale to measure hind 
limb function at various time points after injury. The 
scale assesses 10 different categories, including limb 
movement and tail position. Sham operated animals 
scored 21 on the BBB scale, whereas the SCI animals with 
complete hind limb paralysis scored 0. Experimental ani-
mals were tested after SCI on days 3, 7, 14, 21, and 28. 
Each group consisted of at least 6 animals. Evaluations 
were made by two investigators blinded to the experi-
mental groups.Shunmugavel et al. Journal of Inflammation 2010, 7:17
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Bladder analyses
Bladders of experimental animals were emptied by gentle 
abdominal massage. At indicated times following SCI, the 
animals were sacrificed with intra peritoneal injections of 
sodium pentobarbital. After proper bladder emptying, 
they were perfused with PBS followed by neutral formalin 
solution. The bladders were extracted, weighed and pre-
served in 10% formalin (Fisher, Pittsburgh, PA, USA) for 
further fixation. Images of bladders were scanned, and 
the area of the images was calculated using BioRad Quan-
tity One 4.6.5 image analysis software.
Urine analyses
Animals were given abdominal massage to empty the 
bladder three times a day at 8.00, 13.00 and 20.00 hrs reg-
ularly, and the 12 h urine was used to measure volume, 
osmolality, and protein level. Osmolality was measured 
with a Microsmette (freezing point depression osmome-
try) instrument per the instructions of the manufacturer 
(Precision systems Inc, MA, USA). Each sample was mea-
sured in triplicate. Urine protein concentration was mea-
sured by the Bradford protein assay method. Plasma 
collected from 100 μl blood from the caudal vein was also 
analyzed in the same way.
Histology
At designated time points, the animals were anesthetized 
with intra peritoneal injections of sodium pentobarbital 
and then transcardially perfused with PBS followed by 
neutral formalin solution. Bladder and kidney tissues 
were removed and fixed in 10% formalin solution. After 
fixation, the tissues were processed following routine his-
tological procedures. Tissues were dehydrated in series of 
alcohol and infiltrated with paraffin wax (M.P 60°C) using 
Leica TP-1020 automatic tissue processor. Tissue blocks 
were sectioned (8 μm) with Leica HM-325 rotary micro-
tome. Sections were adhered on to super frost plus gold 
slides (Fisher Scientific Inc, MA, USA). After suitable 
drying time, the sections were deparaffinized in 2 
changes of xylene for 10 minutes each. Sections were 
rehydrated by passing through decreasing grades of etha-
nol (100, 95, 80, 70, and 30%) and water. Sections for 
morphological studies were processed and stained with 
hematoxylin and eosin (H&E) as described previously 
[32].
Immunofluorescence study
Deparaffinized and rehydrated slides were boiled in anti-
gen unmasking solution (Vector Labs, Burlingame, CA) 
for 10 min, cooled for 20 min, and washed with Tris-
sodium buffer (0.1 M Tris-HCl, pH-7.4, and 0.15 M NaCl) 
with 0.05% Tween 20 (TNT) three times each for 5 min. 
The sections were then treated with trypsin (0.1% for 10 
min). Endogenous peroxidase activity was eliminated by 
treating the section with 3% hydrogen peroxide solution 
for 10 min. Sections were blocked in TNT buffer with 
0.5% blocking reagent (TNB, supplied with TSA-Direct 
kit; NEN Life Sciences, Boston MA) for 30 min to reduce 
nonspecific staining. The sections were incubated over-
night with anti caspase-3 antibody (Santa Cruz, CA, 
USA; 1:200) at 4°C. After washing with PBS, the sections 
were stained with Alexafluor 488 (Molecular Probes, 
Invitrogen, CA, USA) flurophore conjugated secondary 
antibody. The tissue fluorescence pattern was observed 
and recorded with a Leica TCS SP5 Laser scanning 
microscope.
Statistical analysis
Statistical analysis was performed by student t test using 
Graph pad -software. Data are expressed as mean ± stan-
dard deviation (SD). P < 0.05 was considered statistically 
significant.
Results
Simvastatin improves locomotor behavior in SCI rats
SCI is associated with apoptotic neuronal loss resulting in 
compromised locomotor functions. We confirmed the 
severity and consistency of SCI by the paraplegic out-
come of the experimental animals. The effect of simvasta-
tin in restoring locomotor behavior was evaluated by BBB 
score after SCI. The sham animals consistently scored 21 
on the BBB locomotor scale. The vehicle treated group 
scored 0.57 ± 0.2 (day 3), 2.78 ± 0.93 (day 7), 6.08 ± 0.39 
(day 14), 6.33 ± 0.35 (day 21), and 6.417 ± 0.41 (day 28) 
post SCI. The simvastatin group scored significantly 
higher (1.71 ± 0.612, 5.583 ± 0.69, 9.33 ± 0.9, 9.92 ± 1.2, 
and 10.58 ± 1.3 on day 3, 7, 14, 21, and 28 post SCI, 
respectively) than the vehicle group animals.
Simvastatin reduces the size and weight of urinary bladder 
in SCI rats
Bladder size and weight changed significantly in animals 
with SCI (Fig 1). The bladder weighed 0.115 ± 0.22 g in 
the sham animals, whereas it was 1.05 ± 0.26 g in SCI ani-
mals, and the increase grew to 9-fold on day 14 after SCI. 
The simvastatin treated group of animals had only a 2.7 
fold increase in bladder weight compared to the sham 
animals (Fig 1A). Bladder volume in terms of area also 
significantly increased in the vehicle group (888.582 ± 
12.42 mm2). The increase in bladder volume compared to 
the sham group was 4.29-fold. The simvastatin-treated 
group had only a 1.85-fold increase in bladder area com-
pared to the sham group (Fig 1B). In contrast, no signifi-
cant difference in body weight loss between vehicle and 
simvastatin groups was observed during the experimental 
period (Fig 2).Shunmugavel et al. Journal of Inflammation 2010, 7:17
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Simvastatin ameliorates voided volume, osmolality, and 
protein level of urine in SCI rats
The volume of voided urine in the bladder gradually 
decreased from day 1 to day 14 in SCI rats (Fig 3). The 
sham animals retained less than 70 μl of urine. Vehicle 
animals retained 1.2 ± 0.13 ml on day 14 after SCI, 
whereas simvastatin animals retained a significantly 
lower volume of urine (0.53 ± 0.01 ml) in the bladder. The 
change in urine to plasma osmolality ratio associated 
with SCI is given in Fig 4. Sham animals showed a ratio of 
6.1 to 7.5 during the study period. The ratio ranged from 
3.6 to 38.6 in the vehicle group. Vehicle animals showed a 
significant increase in the ratio. The simvastatin group of 
animals showed increasingly high urine/plasma osmolal-
ity ratios for 3 days after SCI. Later, the ratio decreased 
gradually and maintained the levels observed in sham 
animals. The quantity of protein excreted through urine 
was significantly elevated in vehicle animals. (Fig 5). The 
urine/plasma protein ratio was 0.124 ± 0.03 in sham ani-
mals. In the vehicle animal, the ratio increased to 1.03 ± 
0.3 and 3.887 ± 0.45 on day 7 and 14, respectively. The 
Figure 3 Simvastatin reduces the voided urine volume after SCI 
in rats. On day 1 post SCI, urine volume was 3.57 ± 0.21 ml in 12 hours. 
In vehicle group, the volume of urine retained in the bladder gradually 
decreased to 1.2 ± 0.13 ml on day 14. Simvastatin treated animals re-
tained significantly lesser volume in the bladder from day 8 to 14. 
Sham animals retained less than 0.07 ml urine on all the days of exper-
iment. Data are expressed as mean ± SD, n = 7.
Figure 4 Simvastatin reduces urine/plasma osmolality ratio after 
SCI in rats. The ratio of urine/plasma osmolality in vehicle group was 
significantly higher than the sham and simvastatin groups from day 3 
onward. Data are expressed as mean ± SD, n = 6. ***p < 0.001.
Figure 1 Simvastain decreases weight and area of bladder after 
SCI in rats. Wet weight (A) and area (B) of bladder of sham, vehicle and 
simvastatin groups were determined at 14 days after SCI. Data are ex-
pressed as mean ± SD, n = 7. **p < 0.01 vs. sham, ## p < 0.01 vs. vehicle.
Figure 2 Effect of simvastatin on body weight of rats after SCI. An-
imal body weight after SCI was reduced significantly in both vehicle 
and simvastatin groups from day 3 to day 7. However, the weight was 
normal at day 14 after SCI in both of the groups. Results are presented 
as % change body weight and data are expressed as mean ± SD, n = 7. 
**p < 0.001 vs. before surgery.Shunmugavel et al. Journal of Inflammation 2010, 7:17
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simvastatin group showed significantly lower levels of 
protein excreted in urine on day 7 as well as day 14 after 
SCI.
Simvastatin improves SCI-induced bladder and renal 
histopathology in SCI rats
In the sham animal bladder, the transitional epithelial 
layer was about 3 cell layers thick and was covered with 
membrane plaque as shown in Fig 6a. The muscular layer 
was thick and compact (Fig 6b). Tunica adventia was thin 
and closely applied to the outer circular muscle layer of 
the bladder (Fig 6c). In the hypertrophied bladder of the 
vehicle treated animals, the transitional epithelial cells 
were several layers thick due to hyperplasia and also 
lacked proper organization (Fig 6d). Lamina propria was 
highly degenerated and was characterized by infiltration 
of cells (Fig 6e). The muscularis layer was highly disorga-
nized, and the number of nuclei per muscle area was also 
decreased. The hypertrophied bladder was also charac-
terized by thick and disorganized tunica adventia, and 
cellular infiltration was evident (Fig 6f). Simvastatin treat-
ment showed remarkable recovery in terms of a reduced 
number of transitional epithelial cell layers and dimin-
ished infiltration of cells (Fig 6g). The muscularis layer 
was also compact (Fig 6h), while the tunica adventia 
thickening and disorganization observed in the vehicle 
treated group was significantly reduced in the simvastatin 
group (Fig 6i).
Simvastatin improves tissue structure and reduces the 
expression of caspase-3 in kidney from SCI rats
The kidney of the sham group showed normal renal 
tubules and glomerular complexes with the glomerular 
complex clear and devoid of any filtrate accumulation 
(Fig 7a). The renal tubules from the vehicle animals 
showed a remarkable degeneration. An accumulation of 
filtrate in the glomerular complex was also evident (Fig 
7b). In addition, the SCI kidney showed crystals in the 
intratubular space. Degeneration of the glomerular wall 
was also seen (Fig 7c). The simvastatin animals showed 
clear renal tubules (Fig 7d). Glomeruli were without accu-
mulation of any filtrate. Renal tubular degeneration was 
also reduced (Fig 7e). Next, we examined the expression 
of caspase-3, an indicator of the apoptotic mechanisms of 
renal tubular epithelial cell loss (Fig 8). Insignificant 
staining observed in the sham kidney indicates the 
absence of caspase-3 activity (Fig 8A). The vehicle kidney 
showed increased caspase-3-positive renal tubules (Fig 
8B), while simvastatin treatment significantly reduced the 
expression of caspase-3 in renal tubules (Fig 8C).
Discussion
The present study shows that post-SCI treatment with 
simvastatin not only reduced the severity of SCI but also 
attenuated SCI-induced pathological damage to the blad-
der and kidney in rats. The improvements in voided urine 
volume, osmolality of urine, and proteinuria correlated 
with recovery of locomotor function in simvastatin-
treated animals.
The post-SCI period is marked by reduced locomotor 
activity, an increased catabolic rate, and nitrogen loss. In 
the present study, we observed a 9-fold increase in blad-
der weight induced by SCI among controls while the ani-
mals treated with simvastatin showed only a 2.7-fold 
increase in bladder weight. The nature of bladder hyper-
trophy is dependent on specific hypertrophying signals; 
for example, SCI-induced spinal bladder is characterized 
by smooth muscle cell hypertrophy of the bladder [9], but 
alloxan-induced bladder hypertrophy does not involve 
smooth muscle hypertrophy [33]. The outlet obstruction 
model induced about a 4-fold increase in rat bladder 
weight [34] and a 6-fold increase in bladder volume at 3 
days after SCI [35]. In addition to weight increase, we also 
observed increased hyperplasia of the transitional epithe-
lial layer and enlarged tunica adventia in the spinal blad-
der. The differing relationship observed between the 
severity of hypertrophy and the hypertrophying signals 
emphasizes that SCI-induced bladder hypertrophy needs 
to be studied as an independent pathology. In addition, as 
SCI patients also show simultaneous contraction of the 
detrusor and sphincter, resulting in detrusor-sphincter 
dyssynergia accompanied by urinary retention and 
increased bladder volume [5], the animal model used in 
the present study fits well for the purpose of delineating 
SCI-induced bladder abnormalities as observed in human 
patients.
The increase in the urine-to-plasma osmolality ratio 
observed in the present study reflects a reduction in 
Figure 5 Simvastatin ameliorates proteinuria after SCI in rats. 
Urine/plasma protein ratio in sham, vehicle and simvastatin groups 
was determined as described in Methods. The ratio was significantly 
reduced in the simvastatin group (0.84 ± 0.16 compared to vehicle 
group (3.89 ± 0.45) on 14th day after SCI. Sham group did not show any 
change in the ratio. Results are expressed as ratio of urine/plasma pro-
teins and data are expressed as mean ± SD, (n = 6).Shunmugavel et al. Journal of Inflammation 2010, 7:17
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glomerular filtration level [36]. Osmolality reflects the 
dehydration and hydration status of the individual [37]. 
Under pathological conditions, low urine osmolality is 
seen with acute renal failure [38] and nephrotoxicity [39]. 
Protein excreted in urine reflects the functional status of 
the kidney [40]. The high urine/plasma protein ratio of 
SCI animals was significantly reduced by simvastatin 
treatment. Statins have previously been reported to 
decrease proteinuria and enhance the glomerular filtra-
tion rate in patients with chronic kidney disease [41,42]. 
Buemi et al have shown fluvastatin to reduce proteinuria 
in IgA nephropathy patients [43]. Damage to glomeruli 
and increased infiltration were evident in the hypertro-
phying bladders of SCI animals, and the degree of dam-
age was less pronounced in the simvastatin group (Fig 7). 
This reduced glomerular damage may occur through the 
direct effect of statins on mesangial cells [44]. Observed 
recovery of the spinal reflex of bladder following SCI has 
varied from 7 [9] to 14 days [4]; however, despite recovery 
of spinal reflex, complete voiding efficiency was not 
recovered [45]. The increased pressure due to retention 
of a large volume of urine in the bladder forces the urine 
back into the ureter and hilus of the kidney, thus disturb-
ing the renal medulla [46] and the cortico-medullary 
interstitial gradient, affecting urine concentration [47]. 
Hence, with increased urine retention and proteinuria, 
we anticipated that bladder hypertrophy would affect 
normal renal architecture. Histological and immunofluo-
Figure 6 Simvastatin improves histomorphology of spinal bladder evaluated at 14th day after SCI in rats. Histomorphology of spinal bladder 
of sham (a-c), vehicle (d-f) and simvastatin group (g-i) was determined by H & E staining. The transitional epithelium was 3 cell layers thick in sham and 
covered with membrane plaque (a; arrow). Hyperplasia and degeneration of epithelial layer and degeneration of lamina propria were observed in 
spinal bladder (d). Muscle layers were thick with little matrix in sham control (b) but degenerated with large matrix deposition in spinal bladder (e; 
arrow). Tunica adventia enclosed large space filled with matrix in spinal bladder (f). Simvastatin treatment significantly decreased the transitional ep-
ithelial hyperplasia (g) muscular hypertrophy (h) and matrix in tunica adventia (i; arrow). Photomicrographs are representative of n = 3 in each group. 
Magnification × 400.Shunmugavel et al. Journal of Inflammation 2010, 7:17
http://www.journal-inflammation.com/content/7/1/17
Page 7 of 10
rescence studies with kidney (Fig 7 &8) supported this 
assumption.
Degeneration of plaques as observed in spinal bladder has 
serious consequences because the urothelium, in addition 
to serving as a passive barrier between urine and detrusor 
muscle, is involved in antigen presentation, micturition 
reflex, and inflammatory regulation [48]. Simvastatin 
treatment preserved the membrane plaques and pro-
tected the underlying urothelium. The simvastatin group 
showed a decreased level of crystals in the kidney (Fig 7d, 
e). This observation is interesting as humans and rats 
have similar crystal-clearing mechanisms [49]. In addi-
tion, statins have already been shown to inhibit renal 
crystal formation in rats [24]. Renal inflammation is one 
of the factors responsible for stone formation [50]. Anti-
inflammatory and neuroprotective properties of statins 
are now well established [18,29,51]. Therefore, the 
reduced number of caspase 3 positive cells in simvasta-
tin-treated rats supports earlier studies of reduced cell 
death by rosuvastatin [52] and atorvastatin (22). How-
ever, the link between locomotion recovery and damage 
to bladder and kidney following SCI is not clear. Our data 
indicate that the degree of bladder/kidney dysfunction 
and their recovery are dependent on the severity of injury 
and the associated myelin/white matter loss at the injury 
site [4]. Simvastatin-mediated recovery of bladder dys-
function may be due, at least in part, to enhanced neuro-
protection within the spinal cord. Increased recovery of 
locomotor behavior and improved renal/bladder func-
tions in simvastatin-treated animals supported the over-
all efficacy of simvastatin therapy in SCI. In addition, 
atorvastatin was also reported to attenuate SCI-induced 
blood spinal cord barrier (BSCB) leakage [28]. We have 
used several statins, including lovastatin, simvastatin and 
Figure 7 Simvastatin improves histomorphology of kidney evaluated at 14th day after SCI in rats. Histomorphology of kidney of sham (a) ve-
hicle (b, c) and simvastatin (d, e) groups was determined by H & E staining. Histology of glomerular complex (arrow) and renal tubules in sham kidney 
was normal. Bladder hypertrophy results in renal tubular degeneration and glomerular dysfunction (b) and formation of crystals (arrow heads) and 
degeneration of glomerular wall (arrow) in spinal bladder kidneys (c). Simvastatin treatment significantly reduced the damage observed with renal 
tubules and glomerular complex (d & e arrows). Photomicrographs are representative of n = 3 in each group. Magnification (a × 400 and b-e × 600).Shunmugavel et al. Journal of Inflammation 2010, 7:17
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atorvastatin, interchangeably with comparable effects in 
animal models of neuroinflammatory diseases, suggest-
ing a class effect of HMG-CoA reductase inhibitors. They 
exert significant effects on oxidative stress and inflamma-
tion within a few hours. However, pleiotropic effects on 
endothelial functions seem to appear earlier for simvasta-
tin than for atorvastatin. Although the half life of atorvas-
tatin is longer (~7 h) [53] than simvastatin (~4.5 h) [54], 
simvastatin's lipophilic qualities determines its superior 
tissue accessibility, thus making it especially promising 
for longer treatment regimens when inflammation is 
diminishing, but repair and recovery are in progress. 
Therefore, simvastatin (5 mg/kg) was elected in this 
study. The dose 5 mg/kg was based on studies with ator-
vastatin in rat SCI models [28,55]. Lower dose such as 0.5 
mg/kg of simvastatin significantly improves functional 
outcome in a rat model of traumatic brain injury [56]. 
Higher dose of simvastatin (20 mg/kg) is reported to be 
toxic in experimental SCI studies [57].
The early recovery of a bladder contraction reflex in sim-
vastatin-treated animals may also be due to the effect of 
the drug on the spinal bladder itself. For example, induc-
tion of inositol 1,4,5 triphosphate (IP3) stimulates the ini-
tial contractile response of bladder smooth muscle [58], 
and simvastatin has been shown to increase the cellular 
level of IP3 [59]. Nevertheless, bladder hypertrophy 
involves several factors, including M2 receptors [60], 
neurotransmitters like glutamate [61], transcriptional 
factors like STAT3 [6], nerve growth factor [62], intracel-
lular calcium [34], transforming growth factor beta [63], 
basic fibroblast growth factor [7], and protein kinase C 
[64]. Therefore, the exact signaling cascade involved in 
simvastatin-mediated bladder and renal functional recov-
ery remains to be elucidated. Nonetheless, the overall 
beneficial effects of statins indicate their potential for 
effecting quick clinical benefits in aiding tissue repair.
Conclusions
The present study suggests that treating SCI patients with 
simvastatin may help to ameliorate bladder and renal dys-
function in addition to providing recovery of locomotor 
functions.
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